Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

NCT06848569 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG: Sintilimab in combination with AVD chemotherapy

Sponsor

Sun Yat-sen University